Pyxis Oncology (Pyxis Oncology) Net Income

: $-73.79 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Pyxis Oncology's Net Income for the three months ended in Dec. 2023 was $-15.60 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-73.79 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Pyxis Oncology's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.35.

Pyxis Oncology Net Income Historical Data

The historical data trend for Pyxis Oncology's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income

-2.77

-12.83

-75.98

-120.72

-73.79

Pyxis Oncology Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income	Get a 7-Day Free Trial											-36.10	-19.24	-15.90	-23.05	-15.60

Pyxis Oncology Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Pyxis Oncology's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-73.79	+	0	+	0	+	0
=	-73.79

Pyxis Oncology's Net Income for the quarter that ended in Dec. 2023 is calculated as

	Net Income		(Q: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-15.597	+	0	+	0	+	0
=	-15.60

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.79 Mil.

Pyxis Oncology (NAS:PYXS) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Pyxis Oncology's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

Earnings per Share (Diluted) (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-15.597	-	0)	/	44.480
	=	-0.35

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Pyxis Oncology Net Income Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Pyxis Oncology (Pyxis Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Cambridgepark Drive, Cambridge, MA, USA, 02140

Website

https://www.pyxisoncology.com

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.

Executives

Pamela Ann Connealy	officer: Chief Financial Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane	officer: Chief Accounting Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan	director, officer: Chief Executive Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont	director	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin	other: Former Director	20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst	officer: Chief Scientific Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140